Literature DB >> 15126785

Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population.

Joseph C Presti1, Una Lee, James D Brooks, Martha K Terris.   

Abstract

PURPOSE: Body mass index (BMI), calculated as weight in kg divided by the square of height in m, is used as an indicator of obesity. We assessed the relationship between BMI, and prostate cancer detection rates and biopsy features in a referral based biopsy population.
MATERIALS AND METHODS: A total of 787 consecutive patients referred for abnormal digital rectal examination and/or prostate specific antigen (PSA) greater than 4 ng/ml underwent systematic prostate biopsy. Three standard categories of BMI were considered, namely normal-less than 25, overweight-25 to 29.9 and obese-30 or greater kg/m. The presence or absence of cancer, percent of core involvement and tumor grade were correlated with BMI. Additional analyses controlled for patient age, PSA and prostate volume.
RESULTS: For the entire population detection rates were highest in the normal BMI group compared to the overweight or obese group (52% vs 37% vs 42%, p = 0.0026). When stratified by age, this observation was true for men younger than 70 years (49% vs 32% vs 37%, p = 0.0042) but not for men 70 years or older. When only patients with PSA 10 ng/ml or less were considered, detection rates were highest in the normal BMI group (44% vs 28% vs 36%, p = 0.0061). This observation also persisted in patients younger than 70 years with PSA 10 ng/ml or less, or when only patients younger than 70 years with a total prostate volume of less than 50 cc were included. Of patients with cancer those with a normal BMI had a greater length of needle core involvement on biopsy.
CONCLUSIONS: Normal BMI correlates with a higher cancer detection rate and larger cancers in men undergoing prostate biopsy.

Entities:  

Mesh:

Year:  2004        PMID: 15126785     DOI: 10.1097/01.ju.0000124847.82541.60

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Best of the 2004 AUA Annual Meeting: Highlights from the 2004 Annual Meeting of the American Urological Association, May 8-13, 2004, San Francisco, CA.

Authors: 
Journal:  Rev Urol       Date:  2004

2.  Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

3.  Reply to "Overweight patients achieve ideal body weight following curative gastrectomy resulting in better long-term prognosis. Letter".

Authors:  Fanming Kong; Hui Li; Xiubao Ren; Xishan Hao
Journal:  Obes Surg       Date:  2013-07       Impact factor: 4.129

4.  Managing localized prostate cancer in the era of prostate-specific antigen screening.

Authors:  James D Brooks
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860

5.  The influence of hepatic function on prostate cancer outcomes after radical prostatectomy.

Authors:  L L Bañez; R M Loftis; S J Freedland; J C Presti; W J Aronson; C L Amling; C J Kane; M K Terris
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-03-02       Impact factor: 5.554

6.  Overweight patients achieve ideal body weight following curative gastrectomy resulting in better long-term prognosis.

Authors:  Fanming Kong; Hui Li; Yongli Fan; Xinwei Zhang; Shui Cao; JinPu Yu; Xiubao Ren; Xishan Hao
Journal:  Obes Surg       Date:  2013-05       Impact factor: 4.129

Review 7.  The impact of obesity on prostate cancer.

Authors:  Joep G H van Roermund; J Alfred Witjes
Journal:  World J Urol       Date:  2007-05-30       Impact factor: 4.226

8.  The Relationship Between Prostate Cancer Aggressiveness and Glycemic Levels in Patients Submitted to Radical Prostatectomy.

Authors:  Suzana Cristina Goncalves; Rafael de Moraes Siqueira; Marcus Vinicius F Nogueira; Joao Antonio Pereira-Correia; Fernando Pires Vaz; Wilza Arantes Ferreira Peres
Journal:  World J Oncol       Date:  2013-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.